Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.

Genetics research - 1 Jun 2015

Hess Gregory P, Fonseca Eileen, Scott Rachel, Fagerness Jesen

Abstract excerpt

Pharmacogenetic/pharmacogenomic (PGx) testing is currently available for a wide range of health problems including cardiovascular disease, cancer, diabetes, autoimmune disorders, mental health disorders and infectious diseases. PGx contributes important information to the field of precision medicine by clarifying appropriate treatments for specific disease subtypes. Tangible benefits to patients including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Outcome Assessment, Health Care

Share to Pharmacogenetics

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 26030725
DOI: 10.1017/S0016672315000099
PMCID: PMC6863636

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.PMID 26030725Read ↗

Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Pharmacogenomics: time to rethink its role in precision medicine.Semantic proximity Read ↗

Theranostics in primary care: pharmacogenomics tests and beyond.Semantic proximity Read ↗

Clinical PharmacogenomicsSemantic proximity Read ↗

Strategies to Improve the Clinical Outcomes for Direct-to-Consumer Pharmacogenomic Tests.Semantic proximity Read ↗

Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical PracticeSemantic proximity Read ↗

Emerging strategies and applications of pharmacogenomics.Semantic proximity Read ↗

Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeuticsSemantic proximity Read ↗

Pharmacogenomics and personalized medicine: mapping of future value creation.Semantic proximity Read ↗

The Economics of Pharmacogenomics.Semantic proximity Read ↗

Pharmacogenomics in clinical practice and drug development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.